Complete Overview of Dengue Vaccine Market 2017 – 2027
Press Release – 18 Jan 2019 Research and Development News -- . . Latest Update "Dengue Vaccine Market: Contribution of NGOs for Better Vaccine Access Expected to Drive the Market in Lower Income Countries: Global Industry Analysis & Opportunity Assessment, 2017 - 2027" with Industries Survey | Global Current Growth and Future. ' ' “Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need” The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takedas TAK-003 and Butantan Institute...